Sirnaomics Ltd.
2257.HK
Get informed when a big investor buys or sells
+ FollowMarket Cap$413.27M
Close$
$0.35
90.8% downside
Current Fair Value
90.8% downsideOvervalued by 90.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $413.27 Million |
|---|---|
| Enterprise Value | $432.37 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.15 |
| Beta | -0.04 |
| Outstanding Shares | 98,947,952 |
Return
| Return on Equity | 406.56% |
|---|---|
| Return on Assets | -183.75% |
| Return on Invested Capital | 152.18% |
Valuation & Multiples
| P/E Ratio | -4.43 |
|---|---|
| PEG | 4.33 |
| Price to Sales | - |
| Price to Book Ratio | -3.8 |
| Enterprise Value to Revenue | 455.6 |
| Enterprise Value to EBIT | -13.62 |
| Enterprise Value to Net Income | -18 |
| Total Debt to Enterprise | 0.06 |
| Debt to Equity | -4.34 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 28, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
April 1, 2027
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Sirnaomics Ltd.
37 employees
CEO: Hung Fai Poon Sirnaomics Ltd. is an RNA therapeutics biopharmaceutical company, founded in 2007 and headquartered in Gaithersburg, Maryland. The company is dedicated to identifying and developing innovative therapeutic compounds aimed at addressing si...